All In Biotech

BLA 125472 · Genentech

Actemra

Tocilizumab · Intravenous, Subcutaneous · Interleukin-6 Receptor Antagonist

Breakthrough therapyOrphan

Last checked: Nov 20, 2026Latest source record: Dec 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Oct 21, 2013

Approved uses

8

Original approval plus efficacy supplements

Registered trials

497

158 Phase 3, 67 recruiting

FAERS reports

115,238

88,232 serious, 12,708 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF SERIOUS INFECTIONS Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) , Adverse Reactions (6.1) ] . Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. If a serious infection develops, interrupt ACTEMRA until the infection is controlled. Reported infections include: Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients, except those with COVID-19, should be tested for latent tuberculosis before ACTEMRA use and during therapy. Treatment for latent infection should be initiated prior to ACTEMRA use. Invasive fungal infections, including candidiasis, aspergillosis, and pneumocystis. Patients with invasive fungal infections may present with...

What it is approved for

From the label in effect Dec 16, 2025.

ACTEMRA ® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) ( 1.3 ) Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.4 ) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.5 ) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Cytokine Release Syndrome (CRS) ( 1.6 ) Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome. Coronavirus Disease 2019 (COVID-19) ( 1.7 ) Hospitalized adult and pediatric patients aged 2 years and older with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). 1.1 Rheumatoid Arthritis (RA) ACTEMRA ® (tocilizumab) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). 1.2 Giant Cell Arteritis (GCA) ACTEMRA ® (tocilizumab) is indicated for the treatment of giant cell arteritis (GCA) in adult...

Mechanism: Tocilizumab binds to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and has been shown to inhibit IL-6-mediated signaling through these receptors. IL-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T- and B-cells, lymphocytes, monocytes and fibroblasts. IL-6 has been shown to be involved in diverse physiological processes such as T-cell activation, induction of immunoglobulin secretion, initiation of hepatic acute phase protein synthesis, and stimulation of hematopoietic precursor cell proliferation and differentiation. IL-6 is...

Therapeutic areas: Immunology and inflammation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 20, 2024 Supplement 56 · Efficacy LabelLetter
  • Mar 4, 2021 Supplement 44 · Efficacy · priority review Breakthrough therapyOrphanLetterLabelReview
  • Nov 19, 2018 Supplement 29 · Efficacy LabelLetter
  • Sep 12, 2018 Supplement 31 · Efficacy · priority review LabelLetter
  • May 11, 2018 Supplement 28 · Efficacy · priority review LabelLetter
  • May 22, 2017 Supplement 24 · Efficacy · priority review Breakthrough therapyLetterLabel
  • Sep 23, 2016 Supplement 18 · Efficacy LabelLetterReview
  • Oct 21, 2013 Original approval · Type 3 - New Dosage Form LetterLabelReview
1 products under this application
  • ACTEMRA · TOCILIZUMAB 162MG/0.9ML · INJECTABLE, INTRAVENOUS, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tocilizumab" as an intervention, any sponsor and status, largest first.

All 497 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective35,679
  • rheumatoid arthritis23,001
  • off label use20,832
  • pain20,416
  • arthralgia17,519
  • joint swelling16,527
  • fatigue15,544
  • rash13,899
  • drug intolerance13,224
  • contraindicated product administered12,254
  • arthropathy11,013
  • alopecia10,836

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200611
20074
20083
200916
2010821
20111,172
20121,880
20132,207
20141,912
20152,597
20164,062
20177,492
20187,920
20199,791
202016,812
202112,742
202212,127
20239,468
202411,141
20258,086
20264,974

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Actemra* (Tocilizumab)

2024 spending

$132M

Beneficiaries

4,779

34,207 claims

Per beneficiary

$27,600

$986.45 per unit

View as table
YearSpending
2020$127,856,836
2021$123,904,981
2022$127,758,479
2023$135,711,700
2024$131,902,218

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 827 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.